{Reference Type}: Journal Article
{Title}: Dual-targeting liposomes modified with BTP-7 and pHA for combined delivery of TCPP and TMZ to enhance the anti-tumour effect in glioblastoma cells.
{Author}: Li L;Jing L;Tang Z;Du J;Zhong Y;Liu X;Yuan M;
{Journal}: J Microencapsul
{Volume}: 41
{Issue}: 6
{Year}: 2024 Sep 11
{Factor}: 4.034
{DOI}: 10.1080/02652048.2024.2376114
{Abstract}: <B>UNASSIGNED: </B>To construct a novel nano-carrier with dual ligands to achieve superior anti-tumour efficacy and lower toxic side effects.<BR><B>UNASSIGNED: </B>Liposomes were prepared by thin film hydration method. Ultraviolet, high performance liquid chromatography, nano-size analyser, ultrafiltration centrifugation, dialysis, transmission electron microscope, flow cytometry, Cell Counting Kit-8, confocal laser scanning microscopy, transwell, and tumorsphere assay were used to study the characterisations, cytotoxicity, and in vitro targeting of dg-Bcan targeting peptide (BTP-7)/pHA-temozolomide (TMZ)/tetra(4-carboxyphenyl)porphyrin (TCPP)-Lip.<BR><B>UNASSIGNED: </B>BTP-7/pHA-TMZ/TCPP-Lip was a spheroid with a mean diameters of 143 ± 3.214 nm, a polydispersity index of 0.203 ± 0.025 and a surface charge of -22.8 ± 0.425 mV. The drug loadings (TMZ and TCPP) are 7.40 ± 0.23% and 2.05 ± 0.03% (mg/mg); and the encapsulation efficiencies are 81.43 ± 0.51% and 84.28 ± 1.64% (mg/mg). The results showed that BTP-7/pHA-TMZ/TCPP-Lip presented enhanced targeting and cytotoxicity.<BR><B>UNASSIGNED: </B>BTP-7/pHA-TMZ/TCPP-Lip can specifically target the tumour cells to achieve efficient drug delivery, and improve the anti-tumour efficacy and reduces the systemic toxicity.